CN113209014A - Long-acting cefquinome sulfate suspension injection and preparation process thereof - Google Patents
Long-acting cefquinome sulfate suspension injection and preparation process thereof Download PDFInfo
- Publication number
- CN113209014A CN113209014A CN202010081437.8A CN202010081437A CN113209014A CN 113209014 A CN113209014 A CN 113209014A CN 202010081437 A CN202010081437 A CN 202010081437A CN 113209014 A CN113209014 A CN 113209014A
- Authority
- CN
- China
- Prior art keywords
- parts
- injection
- cefquinome sulfate
- long
- acting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Dispersion Chemistry (AREA)
- Communicable Diseases (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a long-acting cefquinome sulfate suspension injection and a preparation process thereof, and is characterized by comprising the following components in parts by weight: 1-5 parts of cefquinome sulfate, 1-3 parts of a dispersing agent, 1-2 parts of a suspending agent, 1-2 parts of an antioxidant and 1-88 parts of an injection-grade solvent; the preparation process comprises the following steps: step one, heating an injection-grade solvent to 80-90 ℃, respectively and sequentially adding a dispersing agent and a suspending agent, and stirring to dissolve; step two, adding cefquinome sulfate, stirring for dissolving, adding an antioxidant, and stirring uniformly; supplementing the injection-grade solvent to full dose, stirring uniformly, passing through a homogenizer, and sterilizing to obtain the long-acting cefquinome sulfate suspension injection; the effects of accelerating the distribution of the medicine in the body, promoting the medicine to be slowly absorbed after entering the body and prolonging the action time of effective blood concentration are achieved, the defects of reduced medicine content and short action time in the sterilization process caused by unstable medicine are overcome, and the good preparation with long action time and high stability is provided, thereby providing convenience for clinical medication.
Description
Technical Field
The invention belongs to the technical field of veterinary medicines, and particularly relates to a long-acting cefquinome sulfate suspension injection and a preparation process thereof.
Background
Cefquinome (Cefquinome), also known as Cefquinome, under the trade name of cubebat (cobitan), is a product of Herster, Germany (HoechstAG) Cephalosporin antibiotics specially used for animals of the fourth generation developed in 80 s of 20 th century. Cefquinome is usually prepared clinically in the form of sulfate because of its low absorption in the digestive tract. Cefquinome has wide antibacterial and strong bactericidal effects, and can be used for treating Staphylococcus aureus, Streptococcus, Pseudomonas aeruginosa, and Enterobacteriaceae (Escherichia coli, Salmonella, and Klebsiella)Bacillus, citric acid bacteria and serratia marcescens) has strong killing effect, and also has good killing effect on a plurality of methicillin-resistant staphylococcus and enterobacter. Has been widely applied to the clinical treatment of respiratory system infection of pigs and cows and mastitis of cows at home and abroad.
Cefquinome Sulfate (CS) is a cephalosporin antibiotic dedicated to the 4 th generation animals, and is widely used due to its characteristics of strong antibacterial activity, broad antibacterial spectrum, low drug resistance, and the like. However, the drug has short half-life period, needs frequent administration, has large irritation to the body by intramuscular injection, is unstable in chemical property, and is easy to hydrolyze in the structure under acidic or alkaline conditions, so that the clinical application of the drug is greatly limited. Therefore, the cefquinome sulfate medicament which does not need frequent administration, has small irritation, stable chemical property and difficult hydrolysis has very practical value.
Disclosure of Invention
In view of the above, the invention aims to provide a long-acting cefquinome sulfate suspension injection and a preparation process thereof, which solve the problems of drug content reduction and short action time in a sterilization process caused by drug instability, provide a good preparation with long action time and high stability for farmers in China, provide convenience for clinical medication, and have the advantages of lasting suspension of the drug, no wall sticking of the liquid medicine, good needle-through performance, effectively improved bioavailability, improved medication safety and reduced intramuscular injection irritation.
In order to achieve the purpose, the technical scheme of the invention is realized as follows:
the long-acting cefquinome sulfate suspension injection is characterized by comprising the following components in parts by weight: 1-5 parts of cefquinome sulfate, 1-3 parts of a dispersing agent, 1-2 parts of a suspending agent, 1-2 parts of an antioxidant and 1-88 parts of an injection-grade solvent.
The long-acting cefquinome sulfate suspension injection is characterized by comprising the following components in parts by weight: 2.5 parts of cefquinome sulfate, 3 parts of a dispersing agent, 2 parts of a suspending agent, 1 part of an antioxidant and 91.5 parts of an injection-grade solvent.
The long-acting cefquinome sulfate suspension injection and the preparation process thereof are characterized by comprising the following steps of:
step one, heating injection-grade solvent to 80-90 ℃, respectively and sequentially adding dispersing agent and suspending agent, and then stirring to dissolve;
step two, adding cefquinome sulfate, stirring for dissolving, adding an antioxidant, and stirring uniformly;
and step three, supplementing the injection-grade solvent to the full amount, stirring uniformly, passing through a homogenizer, and sterilizing to obtain the long-acting cefquinome sulfate suspension injection.
Wherein, in the first step, the dispersant is one or more than one of beta-cyclodextrin, span-60, ethyl oleate and tween-80, the suspending agent is one or more than one of aluminum monostearate, hydrogenated castor oil, lecithin and beeswax, and the injection solvent is one of soybean oil, olive oil or peanut oil for injection.
The long-acting cefquinome sulfate suspension injection and the preparation process thereof are characterized in that the antioxidant in the step two is one or a mixture of two of vitamins E, BHA, and the stirring time is 20 min.
The long-acting cefquinome sulfate suspension injection and the preparation process thereof are characterized in that the injection-grade solvent is added in 50 parts in the step one, and the stirring time is 10 min.
The long-acting cefquinome sulfate suspension injection and the preparation process thereof are characterized in that after the cefquinome sulfate is dissolved, stirring is carried out for 30min, and then an antioxidant is added.
The long-acting cefquinome sulfate suspension injection and the preparation process thereof are characterized in that the speed of the homogenizer is 1500-.
The long-acting cefquinome sulfate suspension injection and the preparation process thereof are characterized in that the sterilization is ultra-high temperature sterilization, and the time is 20-30 min.
Compared with the prior art, the long-acting cefquinome sulfate suspension injection has the following advantages:
(1) accelerates the distribution of the medicine in the body, promotes the medicine to be slowly absorbed after entering the body, prolongs the action time of effective blood concentration, achieves the purposes of no toxicity and low cost, reduces the medicine use times, and is well received by the majority of farmers.
(2) The defects of low drug content and short action time in the sterilization process caused by unstable drugs are overcome, and the preparation has long action time and high stability and is convenient for clinical medication.
(3) The suspension is lasting, the liquid medicine is not adhered to the wall, the needle dredging performance is excellent, and the bioavailability is effectively improved.
(4) Improve the safety of medication and reduce the irritation of intramuscular injection.
Detailed Description
Unless defined otherwise, technical terms used in the following examples have the same meanings as commonly understood by one of ordinary skill in the art to which the present invention belongs. The test reagents used in the following examples, unless otherwise specified, are all conventional biochemical reagents; the experimental methods are conventional methods unless otherwise specified.
The present invention will be described in detail with reference to examples.
Examples
The long-acting cefquinome sulfate suspension injection consists of the following components in parts by weight: 2.5 parts of cefquinome sulfate, 1 part of beta-cyclodextrin, 60.1 parts of span, 1 part of ethyl oleate, 2 parts of hydrogenated castor oil, 0.5 part of vitamin E, 0.5 part of BHA and 91.5 parts of soybean oil for injection. The specific operation steps are as follows:
(1) heating 50 parts of soybean oil for injection to about 85 ℃, respectively and sequentially adding 1 part of beta-cyclodextrin, 1 part of span-60.1 parts of ethyl oleate and 2 parts of hydrogenated castor oil, and stirring for 10min to dissolve;
(2) adding 2.5 parts of cefquinome sulfate, stirring for 30min, adding 0.5 part of vitamin E and 0.5 part of BHA, and stirring for 20min to completely dissolve;
(3) supplementing injectable oil to full dose, stirring, passing through homogenizer at 2000r/min for 50min, and sterilizing at 105 deg.C for 30min to obtain milky suspension.
The following are experimental analyses and quality evaluations of the products obtained by the examples of the present application:
first, animal experiment
1. Test samples: the long-acting cefquinome sulfate suspension injection is prepared.
2. The test method comprises the following steps: 20 healthy Duroc x Changbai binary hybrid pigs with the weight of 40kg +/-1.5 kg are selected and randomly divided into 2 groups, 10 pigs in each group and half of a male female. A first group: intramuscular injection of 2.5% cefquinome sulfate suspension injection; second group: the prepared long-acting cefquinome sulfate suspension injection is injected intramuscularly. The intramuscular injection mode is that the neck is injected with the cefquinome sulfate suspension injection at one time; before administration, each pig is weighed, sampling time points and interval time of intramuscular injection are determined according to absorption, distribution and elimination rules of the medicament in vivo after pre-test, and 2.5% cefquinome sulfate suspension injection and long-acting cefquinome sulfate suspension injection are injected in neck part intramuscularly at a weight dose of 4 mg/kg. Feeding management of each test group is the same, water drinking and food intake are free, the feed is full-value daily ration without antibacterial drugs, and pharmacokinetic parameters of each test pig group are counted.
3. The test results are shown in the table:
the table shows that the long-acting cefquinome sulfate suspension injection is quickly absorbed, the elimination half-life period is 24.27 hours, and the elimination half-life period of the cefquinome sulfate suspension injection prepared by the Intemet is prolonged by about 16 hours compared with the elimination half-life period of 8.29 hours of the cefquinome sulfate suspension injection prepared by the Intemet, so that the cefquinome sulfate suspension injection is quick in distribution, slow in elimination, prolonged in action time and improved in bioavailability.
Second, quality evaluation
1. The long-acting cefquinome sulfate suspension injection prepared was compared with cefquinome sulfate suspension injection (2.5%) produced by germany hurst, and the comparison was performed after the two were left under the same conditions for 3 days.
2. Measuring the sample 60ml with a 100ml measuring cylinder, sealing, shaking for 30 s, placing 10ml in a graduated test tube (inner diameter 1.0-1.5cm), and detecting to record the phenomenon; taking the evenly shaken sample of the granularity, and determining according to the granularity and granularity distribution determination method; dispersively taking 60ml of a sample to be tested, placing the sample in a measuring cylinder with a plug and 100ml, and recording the phenomenon after shaking for 30 seconds; the content measurement is performed by high performance liquid chromatography.
3. Precisely measuring appropriate amount of related substances (corresponding to 50mg of cefquinome) after shaking, precisely adding 50ml of mobile phase, strongly shaking for 10min, removing oil layer, filtering, and collecting filtrate as sample solution; precisely measure 1ml, place in a 100ml measuring flask, dilute to the scale with mobile phase, shake well, as control solution. Precisely measuring 20ul of each of the reference solution and the sample solution according to the chromatographic conditions under the content determination item, respectively injecting into a liquid chromatograph, and recording the chromatogram until the retention time of the main component peak is 2 times. Dissolving appropriate amount of 5, 6, 7, 8-tetrahydroquinoline with mobile phase, diluting to obtain solution containing 5ug per 1ml, measuring 20ul, injecting into liquid chromatograph, and recording chromatogram.
4. The results of the stability test after 3 months of acceleration are shown in tables 1 and 2:
table 1 physical stability test data
Table 2 chemical stability test data
According to the stability test data of the sample 2.5% and the reference substance (2.5%) after accelerating for 3 months, the sample prepared by the invention has the advantages of slow sedimentation, good redispersion, smooth needle insertion, improved chemical stability and better quality compared with the reference substance in total.
The experimental data show that the beneficial effects of the application are as follows:
(1) accelerates the distribution of the medicine in the body, promotes the medicine to be slowly absorbed after entering the body, prolongs the action time of effective blood concentration, achieves the purposes of no toxicity and low cost, reduces the medicine use times, and is well received by the majority of farmers.
(2) The defects of low drug content and short action time in the sterilization process caused by unstable drugs are overcome, and the preparation has long action time and high stability and is convenient for clinical medication.
(3) The suspension is lasting, the liquid medicine is not adhered to the wall, the needle dredging performance is excellent, and the bioavailability is effectively improved.
(4) Improve the safety of medication and reduce the irritation of intramuscular injection.
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention, and any modifications, equivalents, improvements and the like that fall within the spirit and principle of the present invention are intended to be included therein.
Claims (8)
1. The long-acting cefquinome sulfate suspension injection is characterized by comprising the following components in parts by weight: 1-5 parts of cefquinome sulfate, 1-3 parts of a dispersing agent, 1-2 parts of a suspending agent, 1-2 parts of an antioxidant and 1-88 parts of an injection-grade solvent.
2. The long-acting cefquinome sulfate suspension injection as claimed in claim 1, which is characterized by comprising the following components in parts by weight: 2.5 parts of cefquinome sulfate, 3 parts of a dispersing agent, 2 parts of a suspending agent, 1 part of an antioxidant and 91.5 parts of an injection-grade solvent.
3. The long-acting cefquinome sulfate suspension injection and the preparation process thereof according to claim 1, wherein the long-acting cefquinome sulfate suspension injection comprises the following steps:
step one, heating injection-grade solvent to 80-90 ℃, respectively and sequentially adding dispersing agent and suspending agent, and then stirring to dissolve;
step two, adding cefquinome sulfate, stirring for dissolving, adding an antioxidant, and stirring uniformly;
and step three, supplementing the injection-grade solvent to the full amount, stirring uniformly, passing through a homogenizer, and sterilizing to obtain the long-acting cefquinome sulfate suspension injection.
Wherein, in the first step, the dispersant is one or more than one of beta-cyclodextrin, span-60, ethyl oleate and tween-80, the suspending agent is one or more than one of aluminum monostearate, hydrogenated castor oil, lecithin and beeswax, and the injection solvent is one of soybean oil, olive oil or peanut oil for injection.
4. The long-acting cefquinome sulfate suspension injection and the preparation process thereof as claimed in claim 2, wherein the antioxidant in step two is one or a mixture of two of vitamins E, BHA, and the stirring time is 20 min.
5. The long-acting cefquinome sulfate suspension injection and the preparation process thereof as claimed in claim 3, wherein the injection-grade solvent is added in 50 parts in the first step, and the stirring time is 10 min.
6. The long-acting cefquinome sulfate suspension injection and the preparation process thereof as claimed in claim 3, wherein the cefquinome sulfate needs to be stirred for 30min after being dissolved, and then an antioxidant is added.
7. The long-acting cefquinome sulfate suspension injection and the preparation process thereof as claimed in claim 3, wherein the speed of the homogenizer is 1500-.
8. The long-acting cefquinome sulfate suspension injection and the preparation process thereof as claimed in claim 3, wherein the sterilization is ultra-high temperature sterilization for 20-30 min.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010081437.8A CN113209014A (en) | 2020-01-21 | 2020-01-21 | Long-acting cefquinome sulfate suspension injection and preparation process thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010081437.8A CN113209014A (en) | 2020-01-21 | 2020-01-21 | Long-acting cefquinome sulfate suspension injection and preparation process thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113209014A true CN113209014A (en) | 2021-08-06 |
Family
ID=77085548
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010081437.8A Pending CN113209014A (en) | 2020-01-21 | 2020-01-21 | Long-acting cefquinome sulfate suspension injection and preparation process thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113209014A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117982413A (en) * | 2024-04-03 | 2024-05-07 | 山东恒邦中科生物工程有限公司 | Preparation method of cefquinome sulfate injection |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2508022A1 (en) * | 2002-12-16 | 2004-07-01 | Peter Gerardus Franciscus Cox. | Mastitis treatment |
| CN1705483A (en) * | 2002-10-25 | 2005-12-07 | 阿克佐诺贝尔公司 | Prolonged release pharmaceutical composition |
| CN101822637A (en) * | 2009-12-31 | 2010-09-08 | 天津瑞普生物技术股份有限公司 | Beta-lactam antibiotics-containing suspension injection |
| CN101953784A (en) * | 2009-07-16 | 2011-01-26 | 中国农业大学 | Veterinary suspension containing amoxicillin, colistin sulfate and prednisolone and preparation method thereof |
| CN102319210A (en) * | 2011-09-29 | 2012-01-18 | 武汉回盛生物科技有限公司 | A kind of long-acting veterinary cefquinome sulfate injection and preparation method thereof |
| CN103751103A (en) * | 2014-02-21 | 2014-04-30 | 山东鲁抗立科药业有限公司 | Long-acting cefquinome sulfate injection and preparation method thereof |
| CN104473868A (en) * | 2014-12-01 | 2015-04-01 | 上海同仁药业有限公司 | Cefquinome sulfate suspension injection and preparation method thereof |
| CN104758245A (en) * | 2015-03-10 | 2015-07-08 | 河南牧翔动物药业有限公司 | A cefquinome sulfate oily suspension injection and a preparing method thereof |
| CN106491532A (en) * | 2016-11-01 | 2017-03-15 | 四川美嘉龙生物科技有限公司 | A kind of cefquinome sulfate injection and preparation technology |
-
2020
- 2020-01-21 CN CN202010081437.8A patent/CN113209014A/en active Pending
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1705483A (en) * | 2002-10-25 | 2005-12-07 | 阿克佐诺贝尔公司 | Prolonged release pharmaceutical composition |
| CA2508022A1 (en) * | 2002-12-16 | 2004-07-01 | Peter Gerardus Franciscus Cox. | Mastitis treatment |
| CN101953784A (en) * | 2009-07-16 | 2011-01-26 | 中国农业大学 | Veterinary suspension containing amoxicillin, colistin sulfate and prednisolone and preparation method thereof |
| CN101822637A (en) * | 2009-12-31 | 2010-09-08 | 天津瑞普生物技术股份有限公司 | Beta-lactam antibiotics-containing suspension injection |
| CN102319210A (en) * | 2011-09-29 | 2012-01-18 | 武汉回盛生物科技有限公司 | A kind of long-acting veterinary cefquinome sulfate injection and preparation method thereof |
| CN103751103A (en) * | 2014-02-21 | 2014-04-30 | 山东鲁抗立科药业有限公司 | Long-acting cefquinome sulfate injection and preparation method thereof |
| CN104473868A (en) * | 2014-12-01 | 2015-04-01 | 上海同仁药业有限公司 | Cefquinome sulfate suspension injection and preparation method thereof |
| CN104758245A (en) * | 2015-03-10 | 2015-07-08 | 河南牧翔动物药业有限公司 | A cefquinome sulfate oily suspension injection and a preparing method thereof |
| CN106491532A (en) * | 2016-11-01 | 2017-03-15 | 四川美嘉龙生物科技有限公司 | A kind of cefquinome sulfate injection and preparation technology |
Non-Patent Citations (1)
| Title |
|---|
| 董自亮等: "硫酸头孢喹肟混悬注射液的研制及质量控制", 《黑龙江畜牧兽医》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117982413A (en) * | 2024-04-03 | 2024-05-07 | 山东恒邦中科生物工程有限公司 | Preparation method of cefquinome sulfate injection |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103751103B (en) | A kind of long-acting cefquinome sulfate injection and preparation method thereof | |
| CN109806273B (en) | Compound solution of tulathromycin and gamithromycin, preparation method and application thereof | |
| CN103417512B (en) | A kind of Biomox and preparation method thereof | |
| CN109953997B (en) | Preparation method of tilmicosin preparation | |
| CN113209014A (en) | Long-acting cefquinome sulfate suspension injection and preparation process thereof | |
| CN117530922B (en) | High-stability compound injection for livestock and preparation method and application thereof | |
| CN101982173B (en) | Danofloxacin mesylate-amoxicillin suspension injection applicable to livestock and poultry as well as preparation and application thereof | |
| CN104095871A (en) | Veterinary injection containing lincomycin hydrochloride and spectinomycin sulfate | |
| CN117547513A (en) | Compound amoxicillin soluble powder for livestock and preparation method thereof | |
| CN117379378A (en) | Compound amoxicillin soluble powder for livestock and preparation process thereof | |
| CN113197850A (en) | Oral suspension of iron glucoheptonate and ponazuril and preparation method thereof | |
| CN111714501A (en) | Method for improving dissolution rate of cefquinome sulfate and dissolution rate detection method thereof | |
| CN105232450A (en) | Rifaximin-containing in-situ gel for breast injection and preparation method of rifaximin-containing in-situ gel | |
| CN104586777A (en) | Ceftiofur hydrochloride powder injection as well as preparation method and application thereof | |
| CN102727451B (en) | Cefmetazole-containing pharmaceutical composition | |
| CN113350297B (en) | Tilmicosin dry suspension and preparation method thereof | |
| CN111603475B (en) | Long-acting compound tylonolide injection and preparation method thereof | |
| CN116763777A (en) | Application of 17-hydro-9-dehydroandrographolide-19-sodium sulfate in preparing medicament for treating cow mastitis | |
| CN114557961A (en) | Slow-release enrofloxacin suspension and preparation method thereof | |
| CN110051622B (en) | Improved long-acting cefotaxime sodium injection and preparation method thereof | |
| James et al. | Stability of intravenous admixtures of aztreonam and ampicillin | |
| CN113209015A (en) | Long-acting ceftiofur hydrochloride suspension injection and preparation process thereof | |
| CN113768872B (en) | Talarmycin injection and application thereof | |
| CN111450057A (en) | Cefquinome sulfate self-microemulsion and preparation method thereof | |
| CN110063991B (en) | Compound ceftiofur hydrochloride breast injection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210806 |